Oligonucleotide Synthesis Market Trends, Innovations, and Growth Opportunities in the Biotechnology Landscape
The Oligonucleotide Synthesis Market Size is projected to grow from USD 12.38 Billion in 2024 to USD 44.32 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.23% during the forecast period (2024 - 2032).
The Oligonucleotide Synthesis market has witnessed
significant growth in recent years, driven by the increasing demand for custom
oligo synthesis and the expanding applications of oligonucleotides in research,
diagnostics, and therapeutics. Oligonucleotides, particularly RNA oligonucleotides,
play a crucial role in various biological and molecular processes, making them
essential tools in the fields of genomics, proteomics, and synthetic biology.
Oligonucleotide synthesis involves the chemical synthesis of
short DNA or RNA sequences, commonly known as oligos. These oligos are crucial
in various molecular biology applications, including polymerase chain reaction
(PCR), DNA sequencing, gene
synthesis, and antisense therapy. The market for oligonucleotide synthesis
is driven by the increasing demand for customized oligos with specific
sequences and modifications, allowing researchers to tailor oligos for their
specific experimental needs.
The rise in genomic research, personalized medicine, and the
development of novel therapeutics has fueled the growth of the oligonucleotide
synthesis market. RNA
oligonucleotides, in particular, have gained prominence due to their
versatile applications in gene expression studies, RNA interference (RNAi), and
mRNA-based therapeutics. The development of RNA-based drugs, such as mRNA
vaccines, has further propelled the demand for high-quality RNA
oligonucleotides.
Major Key
Players:
The Oligonucleotide
Synthesis Companies are GE Healthcare (U.S.), Integrated DNA
Technologies, Inc (U.S), Eurogentec S.A (Belgium), Sigma-Aldrich Corporation
(U.S.), Bioautomation Corporation (U.S.), Agilent Technologies Inc. (U.S.),
Thermo Fisher Scientific Inc. (U.S.), Eurofins Genomics (Germany), L.G.C
Biosearch Technologies (U.S.), Nitto Denko Avecia Inc. (Japan), and others.
Recent Development
Sep 2023 The previously announced merger between the
musculoskeletal solutions business Globus Medical and the spine technology
company NuVasive has been completed. Globus Medical and Nuvasive reached an
agreement in February of this year to purchase Nuvasive in an all-stock deal
estimated to be worth $3.1 billion. The combined business will significantly
influence the continuum of care by providing surgeons and patients with a wide
range of musculoskeletal procedural treatments and technologies. Additionally,
it will enhance operational capability, surgeon training, and product
development. The combination is also anticipated to offer a stronger chance for
more revenue and a solid financial base to create value. The extension of Globus
Medical's board of directors from eight to eleven members has been approved
following the terms specified in the merger agreement with NuVasive. Globus
Medical and NuVasive have merged, combining their significant spine and
orthopedic portfolios, global footprint, and commercial reach.
Regional Analysis
Region-specific segmentation of
the oligonucleotide synthesis market, as discussed in the MRFR report, includes
North America, Europe, Asia Pacific (APAC), and the Middle East & Africa
(MEA).
The rise of North America can be
attributed to the constant search for better treatment. The robust healthcare
structure and the infrastructure of the research centers are quite indicative
of that. Regional endeavor for such things is getting mostly driven by chronic
diseases such as cancer and diabetes. Governments and private investors are
equally funding for innovation in the sector, and it can take the regional
market further ahead.
Europe is getting driven by the
same intents like that of North America and is getting amply backed by research
centers and government initiatives. Funding for the regional market is not a
big problem as many pharmaceutical companies from the region are investing
substantially in understanding the gene sequence to develop better drugs. The
APAC region is expected to rise significantly as many of the global titans are
looking at the region as a possible investment opportunity. Infrastructural
benefits and low cost of resources are some alluring factors that are
controlling the market.
Retinal Detachment treatment Market
For More Information, Please Visit @ Market Research Future
Comments
Post a Comment